Skip to main content
SpringerLink
Log in

Conn’s Syndrome

  • Chapter
  • First Online:
Evidence-Based Endocrine Surgery

Abstract

Primary aldosteronism was first described by Dr. Jerome Conn in 1955 as a clinical entity of potassium depletion and hypertension caused by an adrenocortical adenoma [1]. Patients often had episodes of severe muscle weakness and paralysis, tetany and paraesthesias, and hypertension was the rule. At that time, it was believed that it accounted for <1% of hypertension cases [2].

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 79.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 99.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 139.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. Conn JW, Louis LH. Primary aldosteronism, a new clinical entity. Ann Intern Med. 1956;44(1):1–15.

    Article  CAS  Google Scholar 

  2. Ganguly A. Primary aldosteronism. N Engl J Med. 1998;339(25):1828–34.

    Article  CAS  Google Scholar 

  3. Milliez P, Girerd X, Plouin PF, Blacher J, Safar ME, Mourad JJ. Evidence for an increased rate of cardiovascular events in patients with primary aldosteronism. J Am Coll Cardiol. 2005;45(8):1243–8.

    Article  CAS  Google Scholar 

  4. Chao C-T, Wu V-C, Kuo C-C, Lin Y-H, Chang C-C, Chueh SJ, et al. Diagnosis and management of primary aldosteronism: An updated review. Annals of Medicine 2013;45(4):375–383.

    Article  CAS  Google Scholar 

  5. Rossi GP, Bernini G, Caliumi C, Desideri G, Fabris B, Ferri C, et al. A prospective study of the prevalence of primary aldosteronism in 1,125 hypertensive patients. J Am Coll Cardiol. 2006;48(11):2293–300.

    Article  CAS  Google Scholar 

  6. Funder JW, Carey RM, Mantero F, Murad MH, Reincke M, Shibata H, et al. The management of primary aldosteronism: case detection, diagnosis, and treatment: an Endocrine Society Clinical Practice Guideline. J Clin Endocrinol Metab. 2016;101(5):1889–916.

    Article  CAS  Google Scholar 

  7. Funder JW, Carey RM, Fardella C, Gomez-Sanchez CE, Mantero F, Stowasser M, et al. Case detection, diagnosis, and treatment of patients with primary aldosteronism: an endocrine society clinical practice guideline. J Clin Endocrinol Metab. 2008;93(9):3266–81.

    Article  CAS  Google Scholar 

  8. Monticone S, Viola A, Tizzani D, Crudo V, Burrello J, Galmozzi M, et al. Primary aldosteronism: who should be screened? Horm Metab Res. 2012;44(3):163–9.

    Article  CAS  Google Scholar 

  9. Calhoun DA, Nishizaka MK, Zaman MA, Harding SM. Aldosterone excretion among subjects with resistant hypertension and symptoms of sleep apnea. Chest. 2004;125(1):112–7.

    Article  CAS  Google Scholar 

  10. Di Murro A, Petramala L, Cotesta D, Zinnamosca L, Crescenzi E, Marinelli C, et al. Renin-angiotensin-aldosterone system in patients with sleep apnoea: prevalence of primary aldosteronism. J Renin-Angiotensin-Aldosterone Syst. 2010;11(3):165–72.

    Article  Google Scholar 

  11. Gonzaga CC, Gaddam KK, Ahmed MI, Pimenta E, Thomas SJ, Harding SM, et al. Severity of obstructive sleep apnea is related to aldosterone status in subjects with resistant hypertension. J Clin Sleep Med. 2010;6(4):363–8.

    PubMed  PubMed Central  Google Scholar 

  12. Pratt-Ubunama MN, Nishizaka MK, Boedefeld RL, Cofield SS, Harding SM, Calhoun DA. Plasma aldosterone is related to severity of obstructive sleep apnea in subjects with resistant hypertension. Chest. 2007;131(2):453–9.

    Article  CAS  Google Scholar 

  13. Sim JJ, Yan EH, Liu IL, Rasgon SA, Kalantar-Zadeh K, Calhoun DA, et al. Positive relationship of sleep apnea to hyperaldosteronism in an ethnically diverse population. J Hypertens. 2011;29(8):1553–9.

    Article  CAS  Google Scholar 

  14. Yang L, Zhang H, Cai M, Zou Y, Jiang X, Song L, et al. Effect of spironolactone on patients with resistant hypertension and obstructive sleep apnea. Clin Exp Hypertens. 2016;38(5):464–8.

    Article  CAS  Google Scholar 

  15. Gaddam K, Pimenta E, Thomas SJ, Cofield SS, Oparil S, Harding SM, et al. Spironolactone reduces severity of obstructive sleep apnoea in patients with resistant hypertension: a preliminary report. J Hum Hypertens. 2010;24(8):532–7.

    Article  CAS  Google Scholar 

  16. Rossi GP. A comprehensive review of the clinical aspects of primary aldosteronism. Nat Rev Endocrinol. 2011;7(8):485–95.

    Article  Google Scholar 

  17. Ahmed AH, Cowley D, Wolley M, Gordon RD, Xu S, Taylor PJ, et al. Seated saline suppression testing for the diagnosis of primary aldosteronism: a preliminary study. J Clin Endocrinol Metab. 2014;99(8):2745–53.

    Article  CAS  Google Scholar 

  18. Magill SB, Raff H, Shaker JL, Brickner RC, Knechtges TE, Kehoe ME, et al. Comparison of adrenal vein sampling and computed tomography in the differentiation of primary aldosteronism. J Clin Endocrinol Metab. 2001;86(3):1066–71.

    CAS  PubMed  Google Scholar 

  19. Kloos RT, Gross MD, Francis IR, Korobkin M, Shapiro B. Incidentally discovered adrenal masses. Endocr Rev. 1995;16(4):460–84.

    CAS  PubMed  Google Scholar 

  20. Young WF, Stanson AW, Thompson GB, Grant CS, Farley DR, van Heerden JA. Role for adrenal venous sampling in primary aldosteronism. Surgery. 2004;136(6):1227–35.

    Article  Google Scholar 

  21. Rossi GP, Auchus RJ, Brown M, Lenders JW, Naruse M, Plouin PF, et al. An expert consensus statement on use of adrenal vein sampling for the subtyping of primary aldosteronism. Hypertension. 2014;63(1):151–60.

    Article  CAS  Google Scholar 

  22. Webb R, Mathur A, Chang R, Baid S, Nilubol N, Libutti SK, et al. What is the best criterion for the interpretation of adrenal vein sample results in patients with primary hyperaldosteronism? Ann Surg Oncol. 2012;19(6):1881–6.

    Article  Google Scholar 

  23. Young WF, Stanson AW. What are the keys to successful adrenal venous sampling (AVS) in patients with primary aldosteronism? Clin Endocrinol. 2009;70(1):14–7.

    Article  Google Scholar 

  24. Miotto D, De Toni R, Pitter G, Seccia TM, Motta R, Vincenzi M, et al. Impact of accessory hepatic veins on adrenal vein sampling for identification of surgically curable primary aldosteronism. Hypertension. 2009;54(4):885–9.

    Article  CAS  Google Scholar 

  25. Matsuura T, Takase K, Ota H, Yamada T, Sato A, Satoh F, et al. Radiologic anatomy of the right adrenal vein: preliminary experience with MDCT. AJR Am J Roentgenol. 2008;191(2):402–8.

    Article  Google Scholar 

  26. Ota H, Seiji K, Kawabata M, Satani N, Omata K, Ono Y, et al. Dynamic multidetector CT and non-contrast-enhanced MR for right adrenal vein imaging: comparison with catheter venography in adrenal venous sampling. Eur Radiol. 2016;26(3):622–30.

    Article  Google Scholar 

  27. Omura K, Ota H, Takahashi Y, Matsuura T, Seiji K, Arai Y, et al. Anatomical variations of the right adrenal vein: concordance between multidetector computed tomography and catheter venography. Hypertension. 2017;69:428.

    Article  CAS  Google Scholar 

  28. Reardon MA, Angle JF, Abi-Jaoudeh N, Bruns DE, Haverstick DM, Matsumoto AH, et al. Intraprocedural cortisol levels in the evaluation of proper catheter placement in adrenal venous sampling. J Vasc Interv Radiol. 2011;22(11):1575–80.

    Article  Google Scholar 

  29. Rossi E, Regolisti G, Perazzoli F, Negro A, Grasselli C, Santi R, et al. Intraprocedural cortisol measurement increases adrenal vein sampling success rate in primary aldosteronism. Am J Hypertens. 2011;24(12):1280–5.

    Article  CAS  Google Scholar 

  30. Stowasser M. Improving the success and reliability of adrenal venous sampling: focus on intraprocedural cortisol measurement. Clin Chem. 2012;58(9):1275–7.

    Article  CAS  Google Scholar 

  31. Rossi GP, Barisa M, Allolio B, Auchus RJ, Amar L, Cohen D, et al. The Adrenal Vein Sampling International Study (AVIS) for identifying the major subtypes of primary aldosteronism. J Clin Endocrinol Metab. 2012;97(5):1606–14.

    Article  CAS  Google Scholar 

  32. Kupers EM, Amar L, Raynaud A, Plouin PF, Steichen O. A clinical prediction score to diagnose unilateral primary aldosteronism. J Clin Endocrinol Metab. 2012;97(10):3530–7.

    Article  CAS  Google Scholar 

  33. Riester A, Fischer E, Degenhart C, Reiser MF, Bidlingmaier M, Beuschlein F, et al. Age below 40 or a recently proposed clinical prediction score cannot bypass adrenal venous sampling in primary aldosteronism. J Clin Endocrinol Metab. 2014;99(6):E1035–9.

    Article  CAS  Google Scholar 

  34. Sze WC, Soh LM, Lau JH, Reznek R, Sahdev A, Matson M, et al. Diagnosing unilateral primary aldosteronism—comparison of a clinical prediction score, computed tomography and adrenal venous sampling. Clin Endocrinol. 2014;81(1):25–30.

    Article  Google Scholar 

  35. Venos ES, So B, Dias VC, Harvey A, Pasieka JL, Kline GA. A clinical prediction score for diagnosing unilateral primary aldosteronism may not be generalizable. BMC Endocr Disord. 2014;14:94.

    Article  Google Scholar 

  36. Mendichovszky IA, Powlson AS, Manavaki R, Aigbirhio FI, Cheow H, Buscombe JR, et al. Targeted molecular imaging in adrenal disease—an emerging role for metomidate PET-CT. Diagnostics (Basel). 2016;6(4):42.

    Article  Google Scholar 

  37. Burton TJ, Mackenzie IS, Balan K, Koo B, Bird N, Soloviev DV, et al. Evaluation of the sensitivity and specificity of (11)C-metomidate positron emission tomography (PET)-CT for lateralizing aldosterone secretion by Conn’s adenomas. J Clin Endocrinol Metab. 2012;97(1):100–9.

    Article  CAS  Google Scholar 

  38. Duncan JL 3rd, Fuhrman GM, Bolton JS, Bowen JD, Richardson WS. Laparoscopic adrenalectomy is superior to an open approach to treat primary hyperaldosteronism. Am Surg. 2000;66(10):932–5; discussion 5–6

    PubMed  Google Scholar 

  39. Haveran LA, Novitsky YW, Czerniach DR, Kaban GK, Kelly JJ, Litwin DE. Benefits of laparoscopic adrenalectomy: a 10-year single institution experience. Surg Laparosc Endosc Percutan Tech. 2006;16(4):217–21.

    Article  Google Scholar 

  40. Meria P, Kempf BF, Hermieu JF, Plouin PF, Duclos JM. Laparoscopic management of primary hyperaldosteronism: clinical experience with 212 cases. J Urol. 2003;169(1):32–5.

    Article  Google Scholar 

  41. Lubikowski J, Uminski M, Andrysiak-Mamos E, Pynka S, Fuchs H, Wojcicki M, et al. From open to laparoscopic adrenalectomy: thirty years’ experience of one medical centre. Endokrynol Pol. 2010;61(1):94–101.

    PubMed  Google Scholar 

  42. Muth A, Ragnarsson O, Johannsson G, Wangberg B. Systematic review of surgery and outcomes in patients with primary aldosteronism. Br J Surg. 2015;102(4):307–17.

    Article  CAS  Google Scholar 

  43. Steichen O, Amar L, Chaffanjon P, Kraimps JL, Menegaux F, Zinzindohoue F. SFE/SFHTA/AFCE consensus on primary aldosteronism, part 6: adrenal surgery. Ann Endocrinol (Paris). 2016;77(3):220–5.

    Article  Google Scholar 

  44. Lim PO, Jung RT, MacDonald TM. Raised aldosterone to renin ratio predicts antihypertensive efficacy of spironolactone: a prospective cohort follow-up study. Br J Clin Pharmacol. 1999;48(5):756–60.

    Article  CAS  Google Scholar 

  45. Parthasarathy HK, Menard J, White WB, Young WF Jr, Williams GH, Williams B, et al. A double-blind, randomized study comparing the antihypertensive effect of eplerenone and spironolactone in patients with hypertension and evidence of primary aldosteronism. J Hypertens. 2011;29(5):980–90.

    Article  CAS  Google Scholar 

  46. Karagiannis A, Tziomalos K, Papageorgiou A, Kakafika AI, Pagourelias ED, Anagnostis P, et al. Spironolactone versus eplerenone for the treatment of idiopathic hyperaldosteronism. Expert Opin Pharmacother. 2008;9(4):509–15.

    Article  CAS  Google Scholar 

  47. Born-Frontsberg E, Reincke M, Rump LC, Hahner S, Diederich S, Lorenz R, et al. Cardiovascular and cerebrovascular comorbidities of hypokalemic and normokalemic primary aldosteronism: results of the German Conn’s Registry. J Clin Endocrinol Metab. 2009;94(4):1125–30.

    Article  CAS  Google Scholar 

  48. Mulatero P, Monticone S, Bertello C, Viola A, Tizzani D, Iannaccone A, et al. Long-term cardio- and cerebrovascular events in patients with primary aldosteronism. J Clin Endocrinol Metab. 2013;98(12):4826–33.

    Article  CAS  Google Scholar 

  49. Savard S, Amar L, Plouin PF, Steichen O. Cardiovascular complications associated with primary aldosteronism: a controlled cross-sectional study. Hypertension. 2013;62(2):331–6.

    Article  CAS  Google Scholar 

  50. Catena C, Colussi G, Nadalini E, Chiuch A, Baroselli S, Lapenna R, et al. Cardiovascular outcomes in patients with primary aldosteronism after treatment. Arch Intern Med. 2008;168(1):80–5.

    Article  CAS  Google Scholar 

  51. Marzano L, Colussi G, Sechi LA, Catena C. Adrenalectomy is comparable with medical treatment for reduction of left ventricular mass in primary aldosteronism: meta-analysis of long-term studies. Am J Hypertens. 2015;28(3):312–8.

    Article  CAS  Google Scholar 

  52. Rossi GP, Bernini G, Desideri G, Fabris B, Ferri C, Giacchetti G, et al. Renal damage in primary aldosteronism: results of the PAPY Study. Hypertension. 2006;48(2):232–8.

    Article  CAS  Google Scholar 

  53. Sechi LA, Novello M, Lapenna R, Baroselli S, Nadalini E, Colussi GL, et al. Long-term renal outcomes in patients with primary aldosteronism. JAMA. 2006;295(22):2638–45.

    Article  CAS  Google Scholar 

  54. Catena C, Colussi G, Sechi LA. Mineralocorticoid receptor antagonists and renal involvement in primary aldosteronism: opening of a new era. Eur J Endocrinol. 2013;168(1):C1–5.

    Article  CAS  Google Scholar 

  55. Fallo F, Pilon C, Urbanet R. Primary aldosteronism and metabolic syndrome. Horm Metab Res. 2012;44(3):208–14.

    Article  CAS  Google Scholar 

  56. Catena C, Lapenna R, Baroselli S, Nadalini E, Colussi G, Novello M, et al. Insulin sensitivity in patients with primary aldosteronism: a follow-up study. J Clin Endocrinol Metab. 2006;91(9):3457–63.

    Article  CAS  Google Scholar 

  57. Fagart J, Hillisch A, Huyet J, Barfacker L, Fay M, Pleiss U, et al. A new mode of mineralocorticoid receptor antagonism by a potent and selective nonsteroidal molecule. J Biol Chem. 2010;285(39):29932–40.

    Article  CAS  Google Scholar 

  58. Colussi G, Catena C, Sechi LA. Spironolactone, eplerenone and the new aldosterone blockers in endocrine and primary hypertension. J Hypertens. 2013;31(1):3–15.

    Article  CAS  Google Scholar 

  59. Choi M, Scholl UI, Yue P, Bjorklund P, Zhao B, Nelson-Williams C, et al. K+ channel mutations in adrenal aldosterone-producing adenomas and hereditary hypertension. Science. 2011;331(6018):768–72.

    Article  CAS  Google Scholar 

  60. Beuschlein F, Boulkroun S, Osswald A, Wieland T, Nielsen HN, Lichtenauer UD, et al. Somatic mutations in ATP1A1 and ATP2B3 lead to aldosterone-producing adenomas and secondary hypertension. Nat Genet. 2013;45(4):440–4. 444e1–2

    Article  CAS  Google Scholar 

  61. Tauber P, Aichinger B, Christ C, Stindl J, Rhayem Y, Beuschlein F, et al. Cellular pathophysiology of an adrenal adenoma-associated mutant of the plasma membrane Ca(2+)-ATPase ATP2B3. Endocrinology. 2016;157(6):2489–99.

    Article  CAS  Google Scholar 

  62. Scholl UI, Goh G, Stolting G, de Oliveira RC, Choi M, Overton JD, et al. Somatic and germline CACNA1D calcium channel mutations in aldosterone-producing adenomas and primary aldosteronism. Nat Genet. 2013;45(9):1050–4.

    Article  CAS  Google Scholar 

  63. Piaditis G, Markou A, Papanastasiou L, Androulakis II, Kaltsas G. Progress in aldosteronism: a review of the prevalence of primary aldosteronism in pre-hypertension and hypertension. Eur J Endocrinol. 2015;172(5):R191–203.

    Article  CAS  Google Scholar 

  64. Mulatero P, Stowasser M, Loh KC, Fardella CE, Gordon RD, Mosso L, et al. Increased diagnosis of primary aldosteronism, including surgically correctable forms, in centers from five continents. J Clin Endocrinol Metab. 2004;89(3):1045–50.

    Article  CAS  Google Scholar 

  65. Stowasser M, Sharman J, Leano R, Gordon RD, Ward G, Cowley D, et al. Evidence for abnormal left ventricular structure and function in normotensive individuals with familial hyperaldosteronism type I. J Clin Endocrinol Metab. 2005;90(9):5070–6.

    Article  CAS  Google Scholar 

  66. Gouli A, Kaltsas G, Tzonou A, Markou A, Androulakis II, Ragkou D, et al. High prevalence of autonomous aldosterone secretion among patients with essential hypertension. Eur J Clin Investig. 2011;41(11):1227–36.

    Article  CAS  Google Scholar 

  67. Piaditis GP, Kaltsas GA, Androulakis II, Gouli A, Makras P, Papadogias D, et al. High prevalence of autonomous cortisol and aldosterone secretion from adrenal adenomas. Clin Endocrinol. 2009;71(6):772–8.

    Article  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Endocrinology, National University Hospital, Singapore, Singapore

    Lip Min Soh

Authors
  1. Lip Min Soh
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Lip Min Soh .

Editor information

Editors and Affiliations

  1. Division of Endocrine Surgery, National University Hospital, Singapore, Singapore

    Rajeev Parameswaran

  2. Department of Endocrine Surgery, SGPGI Hospital, Lucknow, India

    Amit Agarwal

Rights and permissions

Reprints and permissions

Copyright information

© 2018 Springer Science+Business Media Singapore

About this chapter

Check for updates. Verify currency and authenticity via CrossMark

Cite this chapter

Soh, L.M. (2018). Conn’s Syndrome. In: Parameswaran, R., Agarwal, A. (eds) Evidence-Based Endocrine Surgery. Springer, Singapore. https://doi.org/10.1007/978-981-10-1124-5_27

Download citation

  • DOI: https://doi.org/10.1007/978-981-10-1124-5_27

  • Published:

  • Publisher Name: Springer, Singapore

  • Print ISBN: 978-981-10-1123-8

  • Online ISBN: 978-981-10-1124-5

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation